Clindamycin-13C,d3

Clindamycin-13C,d3

• CAS Number: 2140264-63-5
• UNSPSC Description: Clindamycin-13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].
• Target Antigen: Antibiotic; Bacterial; Isotope-Labeled Compounds; Parasite
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Others
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Purity: 99.0
• Solubility: 10 mM in DMSO
• Smiles: O=C([C@@H]1C[C@H](CN1[13C]([2H])([2H])[2H])CCC)N[C@@H]([C@@]2([H])O[C@@H]([C@@H]([C@H]([C@H]2O)O)O)SC)[C@@H](Cl)C
• Molecular Weight: 428.99
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17(1):38.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported